mRNA Products

Description: HiExpress Sleeping Beauty Transposase IVT mRNA is a specialized in vitro transcribed (IVT) messenger RNA designed to express the Sleeping Beauty transposase, a powerful tool for stable gene insertion and long-term expression. This IVT mRNA is optimized for efficient expression and stability, featuring a Cap1 structure at the 5' end, and a poly(A) tail. These modifications enhance the mRNA's stability and translation efficiency, ensuring high levels of transposase protein expression. The Sleeping Beauty transposase system is a non-viral gene delivery method that facilitates the integration of genes into the host genome, allowing for stable and long-term expression. This system is widely used in gene therapy and research applications, including the generation of genetically modified cell lines and the development of CAR-T cell therapies. The use of IVT mRNA for transposase expression provides a transient, non-integrating approach, reducing the risk of long-term side effects associated with viral vector-based methods.

CAT: BRP-02536

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Sleeping Beauty Transposase IVT mRNA (m1Psi modified) is a specialized in vitro transcribed (IVT) messenger RNA designed to express the Sleeping Beauty transposase, a powerful tool for stable gene insertion and long-term expression. This IVT mRNA incorporates N1-methylpseudouridine (m1Ψ), which enhances mRNA stability, reduces immunogenicity, and improves translation efficiency. The mRNA is capped with Cap1, and has a poly(A) tail, further enhancing its stability and translation efficiency. The Sleeping Beauty transposase is a non-viral gene delivery system that facilitates the integration of genes into the host genome, allowing for stable and long-term expression. This system is widely used in gene therapy and research applications, including the generation of genetically modified cell lines and the development of CAR-T cell therapies. The incorporation of m1Ψ in the IVT mRNA has been shown to significantly increase ribosomal +1 frameshifting during mRNA translation, which can enhance the production of functional transposase protein. This IVT mRNA is suitable for applications requiring stable and long-term gene expression, such as gene therapy, functional genomics, and the development of genetically modified organisms. The use of m1Ψ modification ensures efficient protein expression while minimizing immune responses, making it an ideal choice for both in vitro and in vivo studies.

CAT: BRP-02537

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Cre IVT mRNA is a specialized in vitro transcribed (IVT) messenger RNA designed to express the Cre recombinase enzyme, a powerful tool for genetic manipulation and gene editing. Cre recombinase is a tyrosine site-specific DNA recombinase that facilitates precise DNA recombination events by recognizing and recombining two loxP DNA sequences. This enzyme is widely used in biotechnology applications for precise removal or replacement of defective DNA through a highly controlled process that avoids DNA lesions. The IVT mRNA is optimized for efficient expression and stability. It features a Cap1 structure at the 5' end, and a poly(A) tail, all of which enhance the mRNA's stability and translation efficiency. These modifications ensure high levels of Cre recombinase protein expression, making it suitable for applications requiring precise genetic manipulation, such as conditional gene knockout, gene expression studies, and the development of genetically modified organisms. The use of IVT mRNA for transient expression of Cre recombinase provides a flexible and efficient platform for these applications, reducing the risk of long-term side effects associated with viral vector-based methods. This approach is particularly advantageous because it allows for transient, non-integrating expression of the Cre recombinase, minimizing the risk of insertional mutagenesis.

CAT: BRP-02538

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Cre IVT mRNA (m1Ψ) is a specialized in vitro transcribed (IVT) messenger RNA designed to express the Cre recombinase enzyme, a powerful tool for genetic manipulation and gene editing. Cre recombinase is a tyrosine site-specific DNA recombinase that facilitates precise DNA recombination events. It selectively recognizes and recombines two loxP DNA sequences, which are 34-bp asymmetric sites featuring a pair of palindromic recombinase binding elements and an asymmetric spacer region. The recombination process involves the assembly of a tetrameric synaptic complex, cleavage of opposing DNA strands, and formation of a Holliday junction intermediate, ultimately leading to the generation of recombinant products. This IVT mRNA incorporates N1-methylpseudouridine (m1Ψ), which enhances mRNA stability, reduces immunogenicity, and improves translation efficiency. The mRNA is capped with Cap1, and has a poly(A) tail, further enhancing its stability and translation efficiency. These modifications ensure high levels of Cre recombinase protein expression, making it suitable for applications requiring precise genetic manipulation, such as conditional gene knockout, gene expression studies, and the development of genetically modified organisms. Cre recombinase has been widely used in biotechnology applications for precise removal or replacement of defective DNA through a highly controlled process that avoids DNA lesions, making it an effective gene editing technology. The use of IVT mRNA for transient expression of Cre recombinase provides a flexible and efficient platform for these applications, reducing the risk of long-term side effects associated with viral vector-based methods.

CAT: BRP-02539

Appearance: Liquid

Concentration: 1 μg/μL

Description: B18R-E3L IVT mRNA is a synthetically designed, multi-cistronic mRNA composed of the B18R and E3L genes from the vaccinia virus, optimized for human codon usage. It is transcribed in vitro (IVT) and functions to inhibit interferon (IFN) responses, thereby enhancing the expression of non-self RNAs. B18R acts as a decoy receptor to block type I interferon activation, while E3L counteracts cellular IFN effects to inhibit apoptosis. When co-transfected with Simplicon RNA or other mRNA, it significantly reduces IFN-mediated immune activation, stabilizing and boosting the expression of the target RNA. Its ability to mitigate immune responses makes it highly valuable for applications requiring repeated mRNA transfection, such as in vaccine development, gene therapy, and protein expression studies.

CAT: BRP-02540

Appearance: Liquid

Concentration: 1 μg/μL

Description: EGFP LNP-mRNA refers to a lipid nanoparticle (LNP)-encapsulated messenger RNA that encodes enhanced green fluorescent protein (eGFP). This formulation leverages the advanced delivery capabilities of LNPs to efficiently transport the mRNA into cells, where it can be translated into the eGFP protein. EGFP serves as a highly visible and versatile reporter, enabling real-time monitoring of gene expression, protein localization, and cellular dynamics. The LNP system enhances the stability and cellular uptake of the mRNA, overcoming barriers such as degradation and immune recognition. This makes EGFP LNP-mRNA an invaluable tool in biomedical research for visualizing cellular processes, studying gene function, and developing gene-therapy-based treatments.

CAT: BRP-02541

Appearance: Liquid

Concentration: 1 μg/μL

Description: EGFP LNP-mRNA (m1Psi) is a lipid nanoparticle (LNP)-encapsulated messenger RNA that encodes enhanced green fluorescent protein (eGFP) and incorporates the modified nucleobase N1-methylpseudouridine (m1Ψ). This modification enhances the stability and translation efficiency of the mRNA while reducing its immunogenicity, making it a powerful tool for gene expression studies and therapeutic applications. The LNP formulation facilitates efficient cellular uptake and delivery of the mRNA, enabling robust expression of eGFP as a reporter protein. This system is widely used in research for tracking gene expression, as well as in the development of mRNA-based vaccines and therapies, where its stability and reduced immune activation are critical for efficacy and safety.

CAT: BRP-02542

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Firefly Luciferase LNP-mRNA is a high-performance mRNA formulation designed for efficient gene expression and delivery. This product features an optimized Firefly Luciferase gene sequence that ensures robust protein expression in various cell types and organisms. Encapsulated in lipid nanoparticles (LNPs), the mRNA is protected from degradation and efficiently delivered into target cells, facilitating high-level expression of the Firefly Luciferase reporter protein. This system is validated for both in vitro and in vivo applications, making it a versatile tool for gene expression studies, cell tracking, and therapeutic development.

CAT: BRP-02543

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Firefly Luciferase LNP-mRNA (m1Psi) is an advanced mRNA formulation designed for efficient gene expression and delivery. This product incorporates N1-methylpseudouridine (m1Ψ), a modified nucleobase that enhances mRNA stability and reduces immunogenicity. The Firefly Luciferase gene serves as a bioluminescent reporter, allowing for sensitive and quantitative measurement of gene expression in various applications, including gene regulation studies, cell viability assays, and in vivo imaging. The LNP delivery system encapsulates the mRNA, protecting it from degradation and facilitating efficient cellular uptake and intracellular release. This formulation has been validated for high-level expression of Firefly Luciferase in both in vitro and in vivo models, demonstrating its potential for therapeutic and research applications. The combination of m1Ψ modification and LNP encapsulation makes HiExpress Firefly Luciferase LNP-mRNA (m1Psi) a powerful tool for mRNA-based therapies and studies.

CAT: BRP-02544

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Firefly Luciferase GalNAc LNP-mRNA is a specialized mRNA formulation designed for targeted gene expression in hepatocytes, utilizing GalNAc-modified lipid nanoparticles (LNPs) to specifically bind to the asialoglycoprotein receptors (ASGPR) on liver cells, ensuring efficient and targeted delivery. The mRNA is optimized for high-level expression of Firefly Luciferase, a bioluminescent reporter protein ideal for in vivo imaging and gene expression studies. Validated in Ldlr-/- mice models, this product offers robust liver-targeted expression, making it a powerful tool for research and therapeutic applications, particularly in the development of liver-specific gene therapies.

CAT: BRP-02545

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Firefly Luciferase GalNAc LNP-mRNA (m1Ψ substitution) is a specialized mRNA product designed for targeted gene expression in hepatocytes. This formulation incorporates N1-methylpseudouridine (m1Ψ) to enhance mRNA stability and reduce immunogenicity. The GalNAc-modified lipid nanoparticles (LNPs) are designed to target the asialoglycoprotein receptors (ASGPR) on hepatocytes, providing an efficient delivery system for gene expression in the liver. The Firefly Luciferase gene is optimized for high-level expression, making it suitable for both in vitro and in vivo applications, such as monitoring gene expression and conducting functional studies. This product has been validated for robust expression in various experimental settings, including in Ldlr-/- mice models, demonstrating its efficacy for targeted delivery and expression.

CAT: BRP-02546

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Cre LNP-mRNA is a specialized mRNA product designed for efficient gene expression and delivery, particularly useful in applications requiring Cre recombinase activity. This formulation encodes Cre recombinase, a powerful enzyme used for site-specific recombination in genetic studies, allowing for conditional gene expression and knockout experiments. The mRNA is encapsulated in lipid nanoparticles (LNPs), which facilitate efficient cellular uptake and intracellular release, ensuring high-level expression of Cre recombinase. This product is ideal for applications in both in vitro and in vivo models, providing a reliable and efficient solution for precise genetic manipulation. It has been validated in various models, including HEK293T cells and mouse models, demonstrating robust expression and functionality. The HiExpress Cre LNP-mRNA is available in both unmodified and m1Ψ-modified forms, with the m1Ψ substitution enhancing mRNA stability and reducing immunogenicity. This makes it suitable for a wide range of applications, including conditional gene expression studies, gene therapy development, and in vivo imaging.

CAT: BRP-02547

Appearance: Liquid

Concentration: 1 μg/μL

Description: HiExpress Cre LNP-mRNA (m1Ψ substitution) is a specialized mRNA product designed for efficient gene expression and delivery, incorporating N1-methylpseudouridine (m1Ψ) to enhance stability and reduce immunogenicity. This formulation encodes Cre recombinase, a powerful enzyme used for site-specific recombination in genetic studies, allowing for conditional gene expression and knockout experiments. The use of m1Ψ in the mRNA has been shown to increase translation efficiency and reduce activation of immune sensors, making it suitable for both in vitro and in vivo applications. This product is encapsulated in lipid nanoparticles (LNPs), which facilitate efficient cellular uptake and intracellular release, ensuring high-level expression of Cre recombinase. It has been validated in various models, including HEK293T cells and mouse models, demonstrating robust expression and functionality. The m1Ψ substitution also helps in avoiding the innate immune response, which is crucial for prolonged expression and repeated dosing in therapeutic applications. This makes HiExpress Cre LNP-mRNA (m1Ψ substitution) an ideal tool for precise genetic manipulation in research and therapeutic development, particularly in applications requiring targeted gene editing and expression control.

CAT: BRP-02548

Appearance: Liquid

Concentration: 1 μg/μL

Description: CleanCap M6 mCherry mRNA (N1MePsU) is a specialized mRNA product encoding the red fluorescent protein mCherry, derived from Discosoma sp. This mRNA is capped using CleanCap M6 technology, which produces a base-modified Cap-1 structure with superior in vivo activity compared to traditional Cap-0 mRNA. The mRNA is also modified with N1-methylpseudouridine (N1MePsU), which enhances translational efficiency and reduces immunogenicity. These modifications result in increased protein expression and improved mRNA stability, making it ideal for applications such as live-cell imaging, reporter gene studies, and optimization of mRNA delivery protocols.

CAT: BRP-02554

Concentration: 1.0 mg/mL

Description: CleanCap M6 FLuc mRNA (N1MePsU) is a specialized mRNA product encoding firefly luciferase (FLuc), a commonly used bioluminescent reporter protein. This mRNA is capped using CleanCap M6 technology, which produces a base-modified Cap-1 structure with superior in vivo activity compared to traditional Cap-0 mRNA. The mRNA is fully substituted with N1-methylpseudouridine (N1MePsU), a modified nucleotide that enhances translational efficiency and reduces immunogenicity, resulting in increased protein expression and safety. This product is ideal for applications such as reporter gene studies, gene expression analysis, and cell viability assays.

CAT: BRP-02555

Concentration: 1.0 mg/mL

Description: CleanCap M6 EGFP mRNA (N1MePsU) is a specialized mRNA product encoding Enhanced Green Fluorescent Protein (EGFP), which is commonly used as a direct detection reporter in mammalian cell culture. This mRNA is capped using CleanCap M6 technology, which produces a base-modified Cap-1 structure with superior in vivo activity compared to traditional Cap-0 mRNA. The mRNA is also modified with N1-methylpseudouridine (N1MePsU), which enhances translational efficiency and reduces immunogenicity. These modifications result in increased protein expression and improved mRNA stability, making it ideal for applications such as live-cell imaging, gene expression studies, and optimization of mRNA delivery protocols.

CAT: BRP-02556

Concentration: 1.0 mg/mL

Description: CleanCap FLuc mRNA is a specialized product designed for high efficiency and stability in gene expression studies. This mRNA expresses firefly luciferase (FLuc), a bioluminescent reporter protein commonly used to measure gene expression and cell viability. The mRNA is capped using CleanCap Reagent AG, which produces a base-modified Cap-1 structure with superior in vivo activity compared to traditional Cap-0 mRNA. This capping method ensures high efficiency and enhanced protein expression. This product is ideal for applications such as reporter gene studies, gene expression analysis, and cell viability assays, providing researchers with a powerful tool for studying cellular processes and evaluating the impact of potential therapeutics.

CAT: BRP-02557

Concentration: 1.0 mg/mL

Description: CleanCap EGFP mRNA is a specialized product designed for enhanced expression and stability. This mRNA encodes Enhanced Green Fluorescent Protein (EGFP), a widely used marker for gene expression and protein localization studies. The mRNA features a CleanCap structure, which includes a base-modified Cap-1 structure that enhances in vivo activity compared to traditional Cap-0 mRNA. Additionally, the mRNA may be modified with 5-methoxyuridine (5-moU) to further improve stability and reduce immunogenicity. These modifications result in increased protein expression and improved mRNA stability, making it ideal for applications such as live-cell imaging, gene expression studies, and optimization of mRNA delivery protocols.

CAT: BRP-02558

Concentration: 1.0 mg/mL

Description: CleanCap mCherry mRNA (5moU) is a specialized mRNA product encoding the red fluorescent protein mCherry, derived from the coral Discosoma sp.. It features a Cap-1 structure and is modified with 5-methoxyuridine (5moU) to enhance translational efficiency and reduce immunogenicity. With an excitation maximum at 587 nm and an emission maximum at 610 nm, mCherry provides bright and stable fluorescence, making it ideal for live-cell imaging, flow cytometry, and gene editing applications. This product is particularly useful for studying cellular processes, optimizing mRNA delivery protocols, and evaluating the impact of potential therapeutics.

CAT: BRP-02559

Concentration: 1.0 mg/mL

Description: CleanCap FLuc mRNA (5moU) is a specialized mRNA product encoding firefly luciferase (FLuc), a bioluminescent reporter protein widely used for measuring gene expression and cell viability. This mRNA is capped using CleanCap Reagent AG, which produces a base-modified Cap-1 structure with superior in vivo activity compared to traditional Cap-0 mRNA. The mRNA is fully substituted with 5-methoxyuridine (5moU), which reduces immunogenicity and enhances translational efficiency, resulting in increased protein expression and improved mRNA stability. This product is ideal for applications such as reporter gene studies, gene expression analysis, and optimization of mRNA delivery protocols.

CAT: BRP-02560

Concentration: 1.0 mg/mL